** U.S.-listed shares of Dutch drugmaker uniQure NV QURE.O down 1.1% to $48.51 on Weds after $225 mln follow-on offering priced

** QURE sold ~4.9 mln shares at $45.50, a 7.2% discount to stock's last sale on Tues

** Offering size increased from $150 mln

** QURE shares surged 78% last Weds after U.S. FDA reversed its earlier position and said it will accept existing trial data for an accelerated review of co's Huntington's disease therapy, AMT-130

** QURE intends to use net offering proceeds to fund potential commercial launches of AMT-130, and to develop other product candidates, among other purposes, per the prospectus

** Leerink Partners, Stifel, Guggenheim and RBC acting as joint bookrunners

** U.S.-listed shares have doubled YTD. They were trading around $14 a year ago

** 13 of 15 analysts rate the shares "strong buy" or "buy", 2 "hold"; median PT $60.50, per LSEG